About Wanbangde Pharmaceutical Holding Group Company

The company always adheres to science and technology as the lead, has a complete R&D system and a R&D team with a high level of expertise and independent innovation capabilities, and has established R&D platforms such as “China Pharmaceutical University - Wanbond Traditional Chinese Medicine Modernization Joint Research Center”, “Zhejiang University - Wanbond Traditional Chinese Medicine Modernization Joint Research Center”, “Cardiovascular and Cerebrovascular Drug Provincial High-tech Enterprise Research and Development Center”, and “Model Academician Expert Workstation”. The company is mainly engaged in R&D, production and sales of modern traditional Chinese medicines, chemical raw materials and chemical preparations; development, production and sales of orthopedic implants and disposable sterile medical polymer devices. The company's main products: thoracolumbar fusion devices, cervical fusion devices, spinal fixation systems, independent condyle and knee fusions, sterile syringes (needles), self-destructing syringes, self-destructing syringes, automatic needle retractable safety syringes, disposable infusion (blood) devices, precision filtration infusions, TPE infusions, infusion tubes, blood collection tubes, ginkgo biloba drops, cyproxacin injections, resorcinin hydrochloride tablets, sulpiride, salt tablets chlorpromazine tablets, etc. Company honors include China's top 20 construction profile enterprises, Zhejiang Province's top 100 fastest growing enterprises, Zhejiang Province's leading demonstration enterprise for transformation and upgrading, Zhejiang Province's clean production stage achievement enterprises, China's top 500 private enterprise manufacturing enterprises, “2022 China's Top 100 Chinese Medicine Enterprises”, “2023-2023 Outstanding Chinese Medicine Brand Enterprise”, and the company's bromhexine hydrochloride tablets are included in the “2023 Comprehensive Statistical Ranking of Chinese OTC Pharmaceutical Products - 2nd Place in Chemical Drugs and Cough-Relieving Phlegm Products”, Huixerine A and Formulation Development and Industrialized applications have obtained honors such as “Scientific and Technological Achievement Registration Certificate”, “2023 Advanced Unit for Monitoring Adverse Drug Adverse Reactions”, and “2024 Zhejiang High-tech Enterprise Top 500 Innovation Capabilities List”.